Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in a Series A financing round led by Sinovac, with contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The proceeds will be used to develop and construct a comprehensive heart failure treatment platform.
Company Overview and Solutions
Founded in 2014, Evaheart Med is an industry platform focused on heart failure, providing full lifecycle solutions that span from prevention, diagnosis, monitoring, and treatment to end-stage assistance. The company is renowned for its implantable left ventricular assist device, EVAHEART, which is touted as the first artificial heart in China. The product has obtained approvals in Europe and Japan and has received IDE approval in the US.
Significance of the Funding
The Series A funding round provides Evaheart Med with the necessary resources to accelerate the development of its heart failure treatment platform. This investment underscores the company’s commitment to advancing innovative solutions for heart failure, enhancing patient care, and expanding its global reach.-Fineline Info & Tech
